Ruder Finn Asia was appointed by the European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, to manage the publicity efforts for the four-day inaugural ESMO Asia Congress 2015 held in Singapore. The Asian edition of ESMO’s annual congress aimed to bridge the gap between researchers, clinicians and patients across disciplines to find the more effective treatment solutions available today. The event, which concluded today, saw close to 3,000 medical professionals representing various oncology disciplines from 75 countries, convening to discuss and share key research and developments in oncology.
The Congress comprised both scientific and educational tracks and delegates were updated on the latest standards of care across different cancer types as recent discoveries in oncology were examined through a range of presentations. Looking forward into the future of cancer care, the area of oncology studies is expected to become increasingly prevalent as the disease continues to plague more individuals globally.
The ESMO Asia 2015 Congress was also an opportunity for young oncologists to present their research and patient cases. In an initiative by the ESMO Young Oncologists Committee (YOC), which provides opportunities to strengthen young oncologists’ skills, knowledge and expertise, while providing a platform for networking with other oncology professionals, young oncologists were invited to submit challenging clinical case studies relevant to the new era of personalised medicine.
ESMO President, Prof Rolf A. Stahel said, “We can and must help improve the outcomes for cancer patients, everywhere. With ESMO’s relentless efforts and dedication, we will continue to support our members in their quest for regular updates. And we’ll remain committed to erasing boundaries in cancer care, whether between countries, continents or specialities, and pursue our mission ‘across oncology, worldwide’.”
Prof Anthony Chan, Co-Chair of the Scientific Committee added, “As the leading professional organisation for medical oncology, ESMO’s presence in Asia underscores the importance and significance of the cancer burden in Asia. As regional and international oncologists form vital networks of information and expertise exchange, this will help to elevate cancer care standards in Asia and around the world.”
Dr Masahiko Nishiyama, who is the Immediate-past Chairman of the Japanese Society of Clinical Oncology added, “Globalisation of clinical oncology is advancing at a very rapid pace. We are already reaching the point at which advanced medical research will be almost impossible in the absence of cooperation studies. We hope that the ESMO Asia Congress will be a platform for our new collaborations.”
Dr Wu Yi-long, Chairman of the Chinese Society of Clinical Oncology said, “ESMO Asia Congress provides a platform that will allow Asian doctors to communicate together. To some extent, it facilitates cooperation among Asian countries themselves to carry out high standards of clinical research and it helps to reduce the imbalance between them. It is the first ESMO Asia Congress, just a beginning.”
The next edition of the ESMO Asia Congress will again be held in Singapore in December 2016.